IP Library Granted Patent US 8,506,972
Granted Patent B2
US 8,506,972 · App. 13/218,516 · Granted Aug 13, 2013

Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions

Inventors: Abdellatif Chenite (Kirkland, CA); Amine Selmani (Montreal, CA)
Assignee: Oligo Medic Inc
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,506,972
App. No.
13/218,516
Granted
Aug 13, 2013
Kind
B2
Abstract

The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting thermogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment.

Claims (31)

1. A biocompatible thermogelling composition comprising:

a) a chitosan solution; and

b) a buffering solution consisting of an amino-sugar carbonate solution, of an amino-sugar phosphate solution, or of a phosphorylated amino-sugar solution;

wherein the composition, being a liquid at a pH between 6.5 and 7.6, is biocompatible, isotonic and turns into gel with time or by lowering or increasing the temperature, said composition forming a gel when heated up to a temperature range between about 25° C. and about 60° C., and cooled down to a temperature range between about 8° C. and about 1° C.

2. The biocompatible thermogelling composition of claim 1 , said composition being liquid at a pH between 6.5 and 7.6 and at a temperature between about 15° C. and about 22° C.

3. The biocompatible thermogelling composition of claim 1 , wherein said buffering solution is a glucosamine carbonate solution, a glucosamine phosphate solution or a glucosamine-6-phosphate solution.

4. The biocompatible thermogelling composition of claim 1 , wherein said thermogelling composition has a pH between 6.7 and 7.2.

5. The biocompatible thermogelling composition of claim 1 , wherein said thermogelling composition turns into gel when heated up to a temperature of 37° C.

6. The biocompatible thermogelling composition of claim 1 , wherein the concentration of chitosan ranges from 0.1% to 5.0%.

7. The biocompatible thermogelling composition of claim 3 , wherein the concentration of glucosamine carbonate, glucosamine phosphate or glucosamine-6-phosphate ranges from 0.002M to 0.100M.

8. The biocompatible thermogelling composition of claim 1 , wherein the concentration of chitosan ranges from 1.0% to about 3.0%.

9. The biocompatible thermogelling composition of claim 3 , wherein the ratio of chitosan to glucosamine carbonate, glucosamine phosphate or glucosamine-6-phosphate is between 1 and 3.

10. The biocompatible thermogelling composition of claim 1 , wherein said chitosan has a degree of deacetylation (DDA) ranging between 70% and 100% and a molecular weight (Mw) ranging from 50 kDa to 1000 kDa.

11. The biocompatible thermogelling composition of claim 10 , wherein said chitosan has a DDA of 80% to 99%, and a Mw of 200 kDa to 500 kDa.

12. The biocompatible thermogelling composition of claim 1 , further comprising at least one material or compound selected from the group consisting of cells, stem cells, peptides, growth factors, human blood, platelet-rich plasma, nucleotides, bone, bone-derived materials, calcium phosphates, calcium carbonates, bioglasses, ceramics, drugs and imaging agents.

13. The biocompatible thermogelling composition of claim 1 , wherein the osmolarity of said composition is between 270 mOsmol/kg and 340 mOsmol/kg.

14. The biocompatible thermogelling composition of claim 1 , wherein said composition is injected to a tissue defect in a patient, then gelled in said tissue defect.

15. The biocompatible thermogelling composition of claim 1 , wherein said composition is pregelled before being injected in a tissue defect in a patient.

16. The biocompatible thermogelling composition of claim 1 , wherein said composition is administered in order to treat, repair, regenerate, replace or substitute, either totally or partially, a tissue or organ within a mammalian or human body.

17. The biocompatible thermogelling composition of claim 16 , wherein the tissue or organ comprises articular cartilage, fibrocartilage, meniscus, intervertebral discs, bone tissues, muscular tissues, nerve and spinal cord soft-tissues, skin or dermal tissues.

18. The biocompatible thermogelling composition of claim 16 , wherein the composition is injected intrarticular to treat or improve body joint functions, or to repair cartilage defects.

19. The biocompatible thermogelling composition of claim 12 , wherein said material or compound is calcium phosphate particles at a concentration comprising between 1.0% and 40.0%.

20. The biocompatible thermogelling composition of claim 19 , wherein said calcium phosphate particles are biphasic calcium phosphates, tetra-calcium phosphates, tri-calcium phosphates, hydroxyapatite, di-calcium phosphates, mono-calcium phosphates, amorphous calcium phosphates, octa-calcium phosphate, fluorinated calcium phosphate, strontied calcium phosphate, or a mixture thereof.

21. The biocompatible thermogelling composition of claim 20 , wherein said biphasic calcium phosphate particles are sized from 50 to 1000 microns.

22. The biocompatible thermogelling composition of claim 20 , wherein said biphasic calcium phosphates comprise:

a) from 20% to 85% of tri-calcium phosphate; and

b) from 80% to 15% of hydroxyapatite.

23. The biocompatible thermogelling composition of claim 19 , wherein said composition is injected and administered as an homogeneous gel.

24. The biocompatible thermogelling composition of claim 23 , wherein said homogeneous gel has a setting time from 1 minute to 30 minutes, and turns into a composite solid scaffold.

25. The biocompatible thermogelling composition of claim 1 , wherein said composition additionally comprises a bioactive agent selected from the group consisting of osteogenic agents, osteoinductive agents, bone morphogenic proteins, cytokines and growth factors.

26. The biocompatible thermogelling composition of claim 1 , wherein said composition is administered to treat, fill or repair bone or osseous defects during the course of a dental, maxillo-facial, spinal or orthopaedic surgery or a traumatological procedure.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2011
From: CHENITE, ABDELLATIF; SELMANI, AMINE
To: OLIGO MEDIC INC.
Reel/Frame 027026/0444 →
Continuity (3)
Provisional Application 61444646 · Feb 18, 2011
Provisional Application 61377592 · Aug 27, 2010
Related Publication 20120052012A1 · Mar 1, 2012